Acta Pharm. 66 (2016) 219-231
Original research paper
Synthesis of some benzimidazole derivatives endowed with 1,2,3-triazole
as potential inhibitors of hepatitis C virus
BAHAA G. M.
YOUSSIF, YASEEN A. M. MOHAMED, MOHAMMED T. A. SALIM, FUYUHIKO INAGAKI, CHISATO MUKAI
and HAJJAJ H. M. ABDU-ALLAH
hajjajabduallah@yahoo.com;
hagag.abdallah@pharm.au.edu.eg
1 Pharmaceutical
Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut, 71526,
Egypt
2 Pharmaceutical Chemistry Department, College of Pharmacy, Al Jouf
University, AlJouf, Sakaka-2014, Kingdom of Saudi Arabia
3 Pharmaceutical Organic Chemistry Department,
Faculty of Pharmacy, Al-Azhar University,Assiut Branch,
Egypt
4 Microbiology and Immunology Department, Faculty of
Pharmacy, Al-Azhar University, Assiut Branch, Egypt
5 Division
of Pharmaceutical Science, Graduate School of Natural Science and Technology, Kanazawa University, Kakuma-machi, Kanazawa
920-1192, Japan
Accepted October 27, 2015
Published online February 25, 2016
New derivatives
of 2-thiobenzimidazole incorporating triazole moiety were synthesized,
characterized and tested in vitro for
antiviral activity against hepatitis C virus (HCV) and hepatitis B virus (HBV).
Their cytotoxicity was determined by the reduction in number of viable cells. All
of the synthesized compounds are inactive against HBV and some showed activity
against HCV. In particular, two compounds showed significant activity, 2-{4-[(1-benzoylbenzimidazol-2-ylthio)methyl]-1H-1,2,3-triazol-1-yl}-N-(p-nitrophenyl)-acetamide
(13) and 2-(4-{[1-(p-chlorobenzoyl)-benzimidazol-2-ylthio)methyl]-1H-1,2,3-triazol-1-yl}-N-(p-nitrophenyl)-acetamide
(17). The results give an insight into the importance of the
substituent at position 2 of benzimidazole for the inhibition of HCV.
Keywords: benzimidazole,
triazole, anilide, antiviral, HCV, HBV